Citations (154)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Amit Yaniv-Rosenfeld, Ariel Rosenfeld & Hagai Maoz. (2023) Hospitalisation outcomes for patients with severe mental illness treated by female vs. male psychiatry residents. International Journal of Psychiatry in Clinical Practice 27:4, pages 338-343.
Read now
Read now
Peter M. Haddad & Christoph U. Correll. (2023) Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opinion on Pharmacotherapy 24:4, pages 473-493.
Read now
Read now
Heather M Fitzgerald, Jason Shepherd, Hollie Bailey, Mia Berry, Jack Wright & Maxine Chen. (2021) Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection. Neuropsychiatric Disease and Treatment 17, pages 3215-3228.
Read now
Read now
James Weatherall, Jacob Simonsen & Brian L. Odlaug. (2020) The relative efficiency of schizophrenia health care systems: an international comparison using data envelopment analysis. Journal of Medical Economics 23:10, pages 1186-1192.
Read now
Read now
Christoph U Correll, Thomas Brevig & Cecilia Brain. (2019) Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists. Neuropsychiatric Disease and Treatment 15, pages 3461-3473.
Read now
Read now
Christoph U Correll, Rakesh Jain, Jonathan M Meyer, Antonia Periclou, Timothy Carrothers, Ágota Barabássy, Mehul Patel & Willie Earley. (2019) Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment 15, pages 2537-2550.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Martha Sajatovic, Ruth Ross, Susan N Legacy, Christoph U Correll, John M Kane, Faith DiBiasi, Heather Fitzgerald & Matthew Byerly. (2018) Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. Neuropsychiatric Disease and Treatment 14, pages 1463-1474.
Read now
Read now
Barbara Remberk, Anna Katarzyna Bażyńska, Joanna Brągoszewska, Piotr Niwiński, Agnieszka Piróg-Balcerzak, Lidia Popek & Filip Rybakowski. (2018) Inpatient psychiatric treatment is not always effective in adolescent sample. International Journal of Psychiatry in Clinical Practice 22:1, pages 70-76.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan & Yu Feng. (2017) Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opinion on Pharmacotherapy 18:17, pages 1799-1809.
Read now
Read now
Mikkel Højlund, Anja Friis Elliott, Nikolaj Juul Madsen, Anne Grethe Viuff, Povl Munk-Jørgensen & Peter Hjorth. (2017) Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. Nordic Journal of Psychiatry 71:8, pages 598-604.
Read now
Read now
Ole Köhler, Henriette Thisted Horsdal, Lone Baandrup, Ole Mors & Christiane Gasse. (2016) Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia. Clinical Epidemiology 8, pages 323-332.
Read now
Read now
Articles from other publishers (142)
Daniel Schöttle, Klaus Wiedemann, Christoph U. Correll, Wolfgang Janetzky, Michael Friede, Holger Jahn & Andreas Brieden. (2023) Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. Schizophrenia Research 260, pages 183-190.
Crossref
Crossref
Kouji Fukuyama, Eishi Motomura & Motohiro Okada. (2023) A Novel Gliotransmitter, L-β-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine. Biomolecules 13:9, pages 1288.
Crossref
Crossref
Vera Battini, Giovanna Cirnigliaro, Rodolfo Leuzzi, Eleonora Rissotto, Giulia Mosini, Beatrice Benatti, Marco Pozzi, Maria Nobile, Sonia Radice, Carla Carnovale, Bernardo Dell’Osso & Emilio Clementi. (2023) The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression. Frontiers in Psychiatry 14.
Crossref
Crossref
Cecilia Maria Esposito, Francesca De Cagna, Alice Caldiroli, Enrico Capuzzi, Alessandro Ceresa, Martina Di Paolo, Anna Maria Auxilia, Martina Capellazzi, Ilaria Tagliabue, Luisa Cirella, Massimo Clerici, Natascia Brondino, Jennifer L. Barkin, Pierluigi Politi & Massimiliano Buoli. (2023) Gender differences in clinical and biochemical parameters among patients hospitalized for schizophrenia: towards precision medicine. European Archives of Psychiatry and Clinical Neuroscience.
Crossref
Crossref
Sang-In Park, Seoyoung Kim, Min-Gul Kim, Hyeong-Seok Lim & Euitae Kim. (2023) Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and Positive and Negative Syndrome Scale Scores. Therapeutic Drug Monitoring 45:3, pages 417-424.
Crossref
Crossref
Roger S McIntyreSara HigaQuan V DoanDiana T AmariDaniel MercerPatrick GillardAmanda Harrington. (2023) Place of care and costs associated with acute episodes and remission in schizophrenia. Journal of Managed Care & Specialty Pharmacy 29:5, pages 499-508.
Crossref
Crossref
Edward Millgate, Sophie E. Smart, Antonio F. Pardiñas, Eugenia Kravariti, Olesya Ajnakina, Adrianna P. Kępińska, Ole A. Andreassen, Thomas R.E. Barnes, Domenico Berardi, Benedicto Crespo-Facorro, Giuseppe D'Andrea, Arsime Demjaha, Marta Di Forti, Gillian A. Doody, Laura Kassoumeri, Aziz Ferchiou, Lorenzo Guidi, Eileen M. Joyce, Ornella Lastrina, Ingrid Melle, Baptiste Pignon, Jean-Romain Richard, Carmen Simonsen, Andrei Szöke, Ilaria Tarricone, Andrea Tortelli, Javier Vázquez-Bourgon, Robin M. Murray, James T.R. Walters & James H. MacCabe. (2023) Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255, pages 173-181.
Crossref
Crossref
Eun-Jeong Joo, Kyu Young Lee, Seong Hoon Jeong & Yong Sik Kim. (2023) Breakthrough Psychosis and Long-Acting Injectable Antipsychotics. Korean Journal of Schizophrenia Research 26:1, pages 1-11.
Crossref
Crossref
Faye McKenna, Pradeep Kumar Gupta, Yu Veronica Sui, Hilary Bertisch, Oded Gonen, Donald C Goff & Mariana Lazar. (2023) Microstructural and Microvascular Alterations in Psychotic Spectrum Disorders: A Three-Compartment Intravoxel Incoherent Imaging and Free Water Model. Schizophrenia Bulletin.
Crossref
Crossref
Lorenzo Del Fabro, Elena Bondi, Francesca Serio, Eleonora Maggioni, Armando D’Agostino & Paolo Brambilla. (2023) Machine learning methods to predict outcomes of pharmacological treatment in psychosis. Translational Psychiatry 13:1.
Crossref
Crossref
Lasse Brandt, Kerstin Ritter, Johannes Schneider-Thoma, Spyridon Siafis, Christiane Montag, Hakan Ayrilmaz, Felix Bermpohl, Alkomiet Hasan, Andreas Heinz, Stefan Leucht, Stefan Gutwinski & Heiner Stuke. (2023) Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis. The Lancet Psychiatry 10:3, pages 184-196.
Crossref
Crossref
Yiguo Tang, Yulu Wu, Xiaojing Li, QinJian Hao, Wei Deng, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Guangya Zhang, Chuanwei Li, Xiangdong Du, Xun Hu, Tao Li & Qiang Wang. (2023) Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent
Responses at Week 6 in a Large-scale Randomized Controlled Trial. Current Neuropharmacology 21:2, pages 424-436.
Crossref
Crossref
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici & Enrico Capuzzi. (2023) High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines 11:2, pages 314.
Crossref
Crossref
Kristin Fjelnseth Wold, Akiah Ottesen, Bärthel Flaaten Camilla, Erik Johnsen, Trine Vik Lagerberg, Kristin Lie Romm, Carmen Simonsen, Torill Ueland, Line Widing, Gina Åsbø & Ingrid Melle. (2023) Early identification of treatment non-response in first-episode psychosis. European Psychiatry 66:1.
Crossref
Crossref
Mishal Qubad & Robert A. Bittner. (2023) Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. Therapeutic Advances in Psychopharmacology 13, pages 204512532311581.
Crossref
Crossref
Andrea de Bartolomeis, Giuseppe De Simone, Mariateresa Ciccarelli, Alessia Castiello, Benedetta Mazza, Licia Vellucci & Annarita Barone. (2022) Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance. Biomedicines 10:12, pages 3183.
Crossref
Crossref
Nagesh Pai, Mustafa Acar, Prabhjot Juneja, Mahsa Hosseini Kouhkamari, Sinthuja Siva & Judy Mullan. (2022) Antipsychotic prescribing patterns in Australia: a retrospective analysis. BMC Psychiatry 22:1.
Crossref
Crossref
Margarita M Maramis, Muhammad Sofyan Almahdy, Atika Atika, Cokorda Bagus Jaya Lesmana & Jakobus Gerick Pantouw. (2021) The biopsychosocial-spiritual factors influencing relapse of patients with schizophrenia. International Journal of Social Psychiatry 68:8, pages 1824-1833.
Crossref
Crossref
Edward Millgate, Kira Griffiths, Alice Egerton, Eugenia Kravariti, Cecilia Casetta, Bill Deakin, Richard Drake, Oliver D Howes, Laura Kassoumeri, Sobia Khan, Steve Lankshear, Jane Lees, Shon Lewis, Elena Mikulskaya, Ebenezer Oloyede, Rebecca Owens, Rebecca Pollard, Nathalie Rich, Sophie Smart, Aviv Segev, Kyra Verena Sendt & James MacCabe. (2022) Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. BMJ Open 12:11, pages e062570.
Crossref
Crossref
Andrea Aguglia, Laura Fusar-Poli, Antimo Natale, Andrea Amerio, Irene Espa, Veronica Villa, Giovanni Martinotti, Giuseppe Carrà, Francesco Bartoli, Armando D’Agostino, Gianluca Serafini, Mario Amore, Eugenio Aguglia, Giovanni Ostuzzi & Corrado Barbui. (2022) Factors Associated with Medication Adherence to Long-Acting
Injectable Antipsychotics: Results from the STAR Network Depot
Study. Pharmacopsychiatry 55:06, pages 281-289.
Crossref
Crossref
Saeed S Shaaban, Rooble Bhullar, Ibrahim Mohammad & Aqeel Hashmi. (2022) A Patient With Schizophrenia in Remission Relapses Following COVID-19: A Case Report. Cureus.
Crossref
Crossref
N. Mørkved, E. Johnsen, R.A. Kroken, D. Winje, T.K. Larsen, J.C. Thimm, M.A. Rettenbacher, C.A. Bartz Johannesen & E.-M. Løberg. (2022) Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial. Schizophrenia Research 246, pages 49-59.
Crossref
Crossref
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, Sakiko Tsugawa, Kazunari Yoshida, Hideaki Tani, Yoji Hirano, Shinsuke Koike, Daiki Sasabayashi, Haruyuki Katayama, Eric Plitman, Kazutaka Ohi, Fumihiko Ueno, Fernando Caravaggio, Teruki Koizumi, Philip Gerretsen, Takefumi Suzuki, Hiroyuki Uchida, Daniel J. Müller, Masaru Mimura, Gary Remington, Anthony A. Grace, Ariel Graff-Guerrero & Shinichiro Nakajima. (2022) Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Molecular Psychiatry 27:7, pages 2950-2967.
Crossref
Crossref
Michael MacKinley, Sabrina D Ford, Peter Jeon, Jean Théberge & Lena Palaniyappan. (2022) Central Oxidative Stress and Early Vocational Outcomes in First Episode Psychosis: A 7-Tesla Magnetic Resonance Spectroscopy Study of Glutathione. Schizophrenia Bulletin 48:4, pages 921-930.
Crossref
Crossref
Hong Seok Oh, Bong Ju Lee, Yu Sang Lee, Ok-Jin Jang, Yukako Nakagami, Toshiya Inada, Takahiro A. Kato, Shigenobu Kanba, Mian-Yoon Chong, Sih-Ku Lin, Tianmei Si, Yu-Tao Xiang, Ajit Avasthi, Sandeep Grover, Roy Abraham Kallivayalil, Pornjira Pariwatcharakul, Kok Yoon Chee, Andi J. Tanra, Golam Rabbani, Afzal Javed, Samudra Kathiarachchi, Win Aung Myint, Tran Van Cuong, Yuxi Wang, Kang Sim, Norman Sartorius, Chay-Hoon Tan, Naotaka Shinfuku, Yong Chon Park & Seon-Cheol Park. (2022) Machine Learning Algorithm-Based Prediction Model for the Augmented Use of Clozapine with Electroconvulsive Therapy in Patients with Schizophrenia. Journal of Personalized Medicine 12:6, pages 969.
Crossref
Crossref
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Naotaka Sunada, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Chikashi Takano, Tomoyo Yanagida, Yosuke Koshikawa, Minami Naito, Atsuko Yamamoto, Masaki Kato & Toshihiko Kinoshita. (2021) Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. CNS Spectrums 27:3, pages 369-377.
Crossref
Crossref
Celso Arango, Jan K. Buitelaar, Christoph U. Correll, Covadonga M. Díaz-Caneja, Maria L. Figueira, W. Wolfgang Fleischhacker, Daniele Marcotulli, Mara Parellada & Benedetto Vitiello. (2022) The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. European Neuropsychopharmacology 59, pages 45-55.
Crossref
Crossref
Christian G. Kohler, Daniel H. Wolf, Anissa Abi-Dargham, Alan Anticevic, Youngsun T. Cho, Clara Fonteneau, Roberto Gil, Ragy R. Girgis, David L. Gray, Jack Grinband, Jonathan A. Javitch, Joshua T. Kantrowitz, John H. Krystal, Jeffrey A. Lieberman, John D. Murray, Mohini Ranganathan, Nicole Santamauro, Jared X. Van Snellenberg, Zailyn Tamayo, Ruben C. Gur, Raquel E. Gur, Monica E. Calkins, Deepak D'Souza, Vinod Srihari, Ralitza Gueorguieva, Prashant Patel, Kimberlee Forselius-Bielen, Jing Lu, Audrey Butler, Geena Fram, Yvette Afriyie-Agyemang, Alexandria Selloni, Laura Cadavid, Sandra Gomez-Luna, Aarti Gupta, Rajiv Radhakrishnan, Ali Rashid, Ryan Aker, Philisha Abrahim, Anahita Bassir Nia, Toral Surti, Lawrence S. Kegeles, Marlene Carlson, Terry Goldberg, James Gangwisch, Erinne Benedict, Preetika Govil, Stephanie Brazis, Megan Mayer, Nathalie de la Garrigue, Natalka Fallon, Topaz Baumvoll, Sameera Abeykoon, Greg Perlman, Kelly Bobchin, Mark Elliott, Lyndsay Schmidt, Sage Rush, Allison Port, Zac Heffernan, Nina Laney, Jenna Kantor & Thomas Hohing. (2022) Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science.
Crossref
Crossref
Giovanni Ostuzzi, Federico Bertolini, Federico Tedeschi, Giovanni Vita, Paolo Brambilla, Lorenzo del Fabro, Chiara Gastaldon, Davide Papola, Marianna Purgato, Guido Nosari, Cinzia Del Giovane, Christoph U. Correll & Corrado Barbui. (2022) Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants. World Psychiatry 21:2, pages 295-307.
Crossref
Crossref
Saeed Farooq, Miriam Hattle, Paola Dazzan, Tom Kingstone, Olesya Ajnakina, David Shiers, Maria Antonietta Nettis, Andrew Lawrence, Richard Riley & Danielle van der Windt. (2022) Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia. BMJ Open 12:4, pages e056420.
Crossref
Crossref
Petros Drosos, Erik Johnsen, Christoffer Andreas Bartz-Johannessen, Tor Ketil Larsen, Solveig Klæbo Reitan, Maria Rettenbacher & Rune Andreas Kroken. (2022) Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. World Journal of Psychiatry 12:3, pages 521-532.
Crossref
Crossref
Christoph U. Correll, Amber Martin, Charmi Patel, Carmela Benson, Rebecca Goulding, Jennifer Kern-Sliwa, Kruti Joshi, Emma Schiller & Edward Kim. (2022) Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia 8:1.
Crossref
Crossref
Meng Wang, Ke Hu, Lingzhong Fan, Hao Yan, Peng Li, Tianzi Jiang & Bing Liu. (2022) Predicting Treatment Response in Schizophrenia With Magnetic Resonance Imaging and Polygenic Risk Score. Frontiers in Genetics 13.
Crossref
Crossref
Christoph U. Correll, Michael Tocco, Andrei Pikalov, Jay Hsu & Robert Goldman. (2022) Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. Schizophrenia Research 240, pages 205-213.
Crossref
Crossref
Xin-Yang Zhang, Huo-Di Chen, Wan-Nian Liang, Xin-Hu Yang, Dong-Bin Cai, Xiong Huang, Xing-Bing Huang, Cheng-Yi Liu & Wei Zheng. (2022) Adjunctive Magnetic Seizure Therapy for Schizophrenia: A Systematic Review. Frontiers in Psychiatry 12.
Crossref
Crossref
Daniel Schöttle, Guerline Clerzius, Wolfgang Janetzky, Oloruntoba Oluboka, Marc-André Roy, François Therrien & Klaus Wiedemann. (2022) Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies. European Psychiatry 65:1.
Crossref
Crossref
Christoph U. Correll, Michael Tocco, Jay Hsu, Robert Goldman & Andrei Pikalov. (2022) Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. European Psychiatry 65:1.
Crossref
Crossref
Subash Raj Susai, Sophie Sabherwal, David Mongan, Melanie Föcking & David R. Cotter. (2021) Omega‐3 fatty acid in ultra‐high‐risk psychosis: A systematic review based on functional outcome. Early Intervention in Psychiatry 16:1, pages 3-16.
Crossref
Crossref
Jose M Rubio & Mercedes Perez-Rodriguez. (2022) Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Michael P Caligiuri, Peter J Weiden, Anna Legedza, Sergey Yagoda & Amy Claxton. (2022) Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Edward Millgate, Olga Hide, Stephen M Lawrie, Robin M Murray, James H MacCabe & Eugenia Kravariti. (2021) Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychological Medicine 52:1, pages 1-13.
Crossref
Crossref
Yuriy Filts, Robert E. Litman, Javier Martínez, Lourdes Anta, Dieter Naber & Christoph U. Correll. (2022) Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophrenia Research 239, pages 83-91.
Crossref
Crossref
Jie Li & Shen Li. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
855
867
.
Klaus Munkholm, Karsten Juhl Jørgensen & Asger Sand Paludan-Müller. (2021) Adverse effects of electroconvulsive therapy. Cochrane Database of Systematic Reviews 2021:12.
Crossref
Crossref
Andrea Aguglia, Laura Fusar-Poli, Andrea Amerio, Valeria Placenti, Carmen Concerto, Giovanni Martinotti, Giuseppe Carrà, Francesco Bartoli, Armando D'Agostino, Gianluca Serafini, Mario Amore, Eugenio Aguglia, Giovanni Ostuzzi & Corrado Barbui. (2021) The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Xin Cheng, Huihui Zhang, Jiuping Zhang, Ping Xu, Peiying Jin, Hui Fang, Kangkang Chu & Xiaoyan Ke. (2021) Comparison of clinical characteristics and treatment efficacy in childhood‐onset schizophrenia and adolescent‐onset schizophrenia in mainland China: A retrospective study. Early Intervention in Psychiatry 15:6, pages 1721-1729.
Crossref
Crossref
Konstantinos N. Fountoulakis, Hans-Jurgen Moeller, Siegfried Kasper, Carol Tamminga, Shigeto Yamawaki, Rene Kahn, Rajiv Tandon, Christoph U. Correll & Afzal Javed. (2020) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectrums 26:6, pages 562-586.
Crossref
Crossref
D. Bugarski-Kirola, B. Abbs, R. Odetalla, I.Y. Liu, M. Darwish, D. DeKarske & S. Stankovic. (2021) P.0775 Adherence to background antipsychotic and pimavanserin in patients with schizophrenia: post hoc analyses from the ENHANCE and ADVANCE trials. European Neuropsychopharmacology 53, pages S565-S566.
Crossref
Crossref
M. V. Assanovich. (2021) PREDICTORS OF THERAPEUTIC RESPONSE AND LENGTH OF HOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA DURING PHARMACOTHERAPY. Journal of the Grodno State Medical University 19:5, pages 532-540.
Crossref
Crossref
Urvakhsh Meherwan Mehta, Ferose Azeez Ibrahim, Manu S. Sharma, Ganesan Venkatasubramanian, Jagadisha Thirthalli, Rose Dawn Bharath, Nicolas R. Bolo, Bangalore N. Gangadhar & Matcheri S. Keshavan. (2021) Resting-state functional connectivity predictors of treatment response in schizophrenia – A systematic review and meta-analysis. Schizophrenia Research 237, pages 153-165.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Lena Palaniyappan, Min Tae M. Park, Peter Jeon, Roberto Limongi, Kun Yang, Akira Sawa & Jean Théberge. (2021) Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?. Antioxidants 10:11, pages 1703.
Crossref
Crossref
Peter Jeon, Roberto Limongi, Sabrina D. Ford, Cassandra Branco, Michael Mackinley, Maya Gupta, Laura Powe, Jean Théberge & Lena Palaniyappan. (2021) Glutathione as a Molecular Marker of Functional Impairment in Patients with At-Risk Mental State: 7-Tesla 1H-MRS Study. Brain Sciences 11:7, pages 941.
Crossref
Crossref
Barbara H. Chaiyachati & Raquel E. Gur. (2021) Effect of child abuse and neglect on schizophrenia and other psychotic disorders. Pharmacology Biochemistry and Behavior 206, pages 173195.
Crossref
Crossref
Mariola Molina-García, David Fraguas, Ángel del Rey-Mejías, Gisela Mezquida, Ana M. Sánchez-Torres, Silvia Amoretti, Antonio Lobo, Ana González-Pinto, Álvaro Andreu-Bernabeu, Iluminada Corripio, Eduard Vieta, Inmaculada Baeza, Anna Mané, Manuel Cuesta, Elena de la Serna, Beatriz Payá, Iñaki Zorrilla, Celso Arango, Miquel Bernardo, Marta Rapado-Castro & Mara Parellada. (2021) The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. Journal of Clinical Medicine 10:11, pages 2474.
Crossref
Crossref
Abel Thamby, Srinivas Balachander, Syed Farooq Ali, Shyam Sundar Arumugham, Jaisoorya TS, Janardhanan C. Narayanaswamy & Y.C Janardhan Reddy. (2021) Naturalistic outcome of medication-naïve obsessive compulsive disorder treated with serotonin reuptake inhibitors. Asian Journal of Psychiatry 60, pages 102642.
Crossref
Crossref
David Fraguas, Covadonga M. Díaz-Caneja, Laura Pina-Camacho, Inge Winter van Rossum, Lone Baandrup, Iris E. Sommer, Birte Glenthøj, René S. Kahn, Stefan Leucht & Celso Arango. (2021) The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study. Schizophrenia Research 231, pages 100-107.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
S. E. Smart, A. P. Kępińska, R. M. Murray & J. H. MacCabe. (2019) Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological Medicine 51:1, pages 44-53.
Crossref
Crossref
Christoph U. Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian & Stephen R. Saklad. (2021) Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs 35:1, pages 39-59.
Crossref
Crossref
Paulina Cieślik & Joanna M. Wierońska. (2020) Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery. International Journal of Molecular Sciences 21:22, pages 8811.
Crossref
Crossref
Christoph U Correll, Koen Demyttenaere, Andrea Fagiolini, Göran Hajak, Stefano Pallanti, Giorgio Racagni & Swaran Singh. (2020) Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. Future Neurology 15:4.
Crossref
Crossref
Minhan Dai, Yulu Wu, Yiguo Tang, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Xun Hu, Guangya Zhang, Xiaodong Du, Qiang Wang & Tao Li. (2020) Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial. BJPsych Open 6:6.
Crossref
Crossref
Robin Emsley, Laila Asmal, Jose M. Rubio, Christoph U. Correll & John M. Kane. (2020) Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophrenia Research 225, pages 55-62.
Crossref
Crossref
Steven G. Potkin, John M. Kane, Christoph U. Correll, Jean-Pierre Lindenmayer, Ofer Agid, Stephen R. Marder, Mark Olfson & Oliver D. Howes. (2020) The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. FOCUS 18:4, pages 456-465.
Crossref
Crossref
Paulo Lizano, Kiranpreet Dhaliwal, Olivia Lutz, Suraj Sarvode Mothi, Jean Miewald, Debra Montrose & Matcheri Keshavan. (2019) Trajectory of neurological examination abnormalities in antipsychotic-naïve first-episode psychosis population: a 1 year follow-up study. Psychological Medicine 50:12, pages 2057-2065.
Crossref
Crossref
Elisabetta Maffioletti, Paolo Valsecchi, Alessandra Minelli, Chiara Magri, Cristian Bonvicini, Stefano Barlati, Emilio Sacchetti, Antonio Vita & Massimo Gennarelli. (2020)
Association study between
HTR2A
rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients
. Drug Development Research 81:6, pages 754-761.
Crossref
Crossref
Kara Dempster, Peter Jeon, Michael MacKinley, Peter Williamson, Jean Théberge & Lena Palaniyappan. (2020) Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Molecular Psychiatry 25:8, pages 1640-1650.
Crossref
Crossref
Mirko Manchia & Bernardo Carpiniello. (2020) Editorial: Decreasing the Impact of Treatment Resistance in Schizophrenia: Identifying Novel Molecular Targets/Pathways to Increase Treatment Efficacy. Frontiers in Pharmacology 11.
Crossref
Crossref
Diogo Ferri Marques, Vanessa Kiyomi Ota, Marcos Leite Santoro, Fernanda Talarico, Giovany Oliveira Costa, Leticia Maria Spindola, Hugo Cogo-Moreira, Carolina Muniz Carvalho, Gabriela Xavier, Daniel Azevedo Cavalcante, Ary Gadelha, Cristiano Noto, Quirino Cordeiro, Rodrigo Affonseca Bressan, Patricia Natalia Moretti & Sintia Iole Belangero. (2020) LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort. Epigenomics 12:12, pages 1041-1051.
Crossref
Crossref
S. Mas, P. Gassó, N. Rodríguez, B. Cabrera, G. Mezquida, A. Lobo, A. González‐Pinto, M. Parellada, I. Corripio, E. Vieta, J. Castro‐Fornieles, J. Bobes, J. Usall, J. Saiz‐Ruiz, F. Contreras, E. Parellada & M. Bernardo. (2019) Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first‐episode psychosis cohort. Acta Psychiatrica Scandinavica 141:6, pages 541-552.
Crossref
Crossref
Jose M. Rubio, Heidi Taipale, Christoph U. Correll, Antti Tanskanen, John M. Kane & Jari Tiihonen. (2019) Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychological Medicine 50:8, pages 1356-1367.
Crossref
Crossref
Ditte Lammers Vernal, Søren Kjærgaard Boldsen, Marlene Briciet Lauritsen, Christoph U. Correll & René Ernst Nielsen. (2020) Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. Schizophrenia Research 220, pages 123-129.
Crossref
Crossref
Sophie E. Legge, Charlotte A. Dennison, Antonio F. Pardiñas, Elliott Rees, Amy J. Lynham, Lucinda Hopkins, Lesley Bates, George Kirov, Michael J. Owen, Michael C. O'Donovan & James T.R. Walters. (2019) Clinical indicators of treatment-resistant psychosis. The British Journal of Psychiatry 216:5, pages 259-266.
Crossref
Crossref
Piyumi Fernando, Iris E.C. Sommer & Alkomiet Hasan. (2020) Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?. Current Opinion in Psychiatry 33:3, pages 192-199.
Crossref
Crossref
Alexandre González-Rodríguez, Armand Guàrdia, Diego José Palao, Javier Labad & Mary V Seeman. (2020) Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed. World Journal of Psychiatry 10:4, pages 34-45.
Crossref
Crossref
Bruno B. Ortiz, Cinthia H. Higuchi, Cristiano Noto, Dan W. Joyce, Christoph U. Correll, Rodrigo A. Bressan & Ary Gadelha. (2020) A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. Schizophrenia Research 218, pages 195-200.
Crossref
Crossref
A. Karow, C. Brettschneider, H. Helmut König, C.U. Correll, D. Schöttle, D. Lüdecke, A. Rohenkohl, F. Ruppelt, V. Kraft, J. Gallinat & M. Lambert. (2020) Better care for less money: cost‐effectiveness of integrated care in multi‐episode patients with severe psychosis. Acta Psychiatrica Scandinavica 141:3, pages 221-230.
Crossref
Crossref
Mary V. Seeman. (2020) Men and women respond differently to antipsychotic drugs. Neuropharmacology 163, pages 107631.
Crossref
Crossref
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U. Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock & Joachim Cordes. (2019) A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 83-94.
Crossref
Crossref
Parita Shah, Yusuke Iwata, Eric E. Brown, Julia Kim, Marcos Sanches, Hiroyoshi Takeuchi, Shinichiro Nakajima, Margaret Hahn, Gary Remington, Philip Gerretsen & Ariel Graff-Guerrero. (2019) Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 11-22.
Crossref
Crossref
Steven G. Potkin, John M. Kane, Christoph U. Correll, Jean-Pierre Lindenmayer, Ofer Agid, Stephen R. Marder, Mark Olfson & Oliver D. Howes. (2020) The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. npj Schizophrenia 6:1.
Crossref
Crossref
Goda Tarcijonas, William Foran, Gretchen L Haas, Beatriz Luna & Deepak K Sarpal. (2020) Intrinsic Connectivity of the Globus Pallidus: An Uncharted Marker of Functional Prognosis in People With First-Episode Schizophrenia. Schizophrenia Bulletin 46:1, pages 184-192.
Crossref
Crossref
Linnea Stenmark, Katarzyna Popiolek, Robert Bodén, Ole Brus, Åsa Hammar, Mikael Landén, Johan Lundberg, Pia Nordanskog & Axel Nordenskjöld. (2020) Predictors of Treatment Response to Electroconvulsive Therapy in Schizophrenia—A Nationwide Registry-Based Study. Schizophrenia Bulletin Open 1:1.
Crossref
Crossref
Scott R. Clark, Micah Cearns, Klaus Oliver Schubert & Bernhard T. Baune. 2020. Personalized Psychiatry. Personalized Psychiatry
521
536
.
Sophie E. Legge, Antonio F. Pardiñas & James T.R. Walters. 2020. Personalized Psychiatry. Personalized Psychiatry
413
422
.
C. U. Correll. (2020) Pharmakotherapie der SchizophreniePharmacotherapy of schizophrenia. Der Nervenarzt 91:1, pages 34-42.
Crossref
Crossref
Jie Li & Shen Li. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
13
.
Deepak K. Sarpal & Anil K. Malhotra. 2020. Neuroimaging in Schizophrenia. Neuroimaging in Schizophrenia
355
366
.
Damodharan Dinakaran, Vanteemar S. Sreeraj & Ganesan Venkatasubramanian. 2020. Schizophrenia Treatment Outcomes. Schizophrenia Treatment Outcomes
85
89
.
Mary V. Seeman. 2020. Schizophrenia Treatment Outcomes. Schizophrenia Treatment Outcomes
15
25
.
Christoph U. Correll, Thomas Brevig & Cecilia Brain. (2019) Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry 19:1.
Crossref
Crossref
J. Lally & F. Gaughran. (2018) Treatment resistant schizophrenia – review and a call to action. Irish Journal of Psychological Medicine 36:4, pages 279-291.
Crossref
Crossref
Luisa Peters, Amanda Krogmann, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. Current Psychiatry Reports 21:12.
Crossref
Crossref
Philip Gorwood, Sophie Bouju, Cécile Deal, Charlotte Gary, Catherine Delva, Sylvie Lancrenon & Pierre-Michel Llorca. (2019) Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. Psychiatry Research 281, pages 112560.
Crossref
Crossref
Goda Tarcijonas & Deepak K. Sarpal. (2019) Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies. Neurobiology of Disease 131, pages 104209.
Crossref
Crossref
Daniel Schöttle, Friederike Ruppelt, Benno G. Schimmelmann, Anne Karow, Alexandra Bussopulos, Jürgen Gallinat, Klaus Wiedemann, Daniel Luedecke, Anja Christine Rohenkohl, Christian G. Huber, Thomas Bock & Martin Lambert. (2019) Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment. Frontiers in Psychiatry 10.
Crossref
Crossref
Marco Solmi, Michele Fornaro, Kuniyoshi Toyoshima, Andrè F. Carvalho, Cristiano A. Köhler, Nicola Veronese, Brendon Stubbs, Andrea de Bartolomeis & Christoph U. Correll. (2018) Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectrums 24:5, pages 479-495.
Crossref
Crossref
Cinzia Molent, Daniele Olivo, Robert Christian Wolf, Matteo Balestrieri & Fabio Sambataro. (2019) Functional neuroimaging in treatment resistant schizophrenia: A systematic review. Neuroscience & Biobehavioral Reviews 104, pages 178-190.
Crossref
Crossref
Hsiao-Fen Hsu, Chia-Chan Kao, Ti Lu, Jeremy C. Ying & Sheng-Yu Lee. (2019) Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services. Journal of Clinical Medicine 8:6, pages 823.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, John M. Kane & Christoph U. Correll. (2019) Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons. World Psychiatry 18:2, pages 208-224.
Crossref
Crossref
Marco Armando, Joost Hutsebaut & Martin Debbané. (2019) A Mentalization-Informed Staging Approach to Clinical High Risk for Psychosis. Frontiers in Psychiatry 10.
Crossref
Crossref
Myrto T Samara, Adriani Nikolakopoulou, Georgia Salanti & Stefan Leucht. (2019) How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. Schizophrenia Bulletin 45:3, pages 639-646.
Crossref
Crossref
Daniela Polese, Michele Fornaro, Mario Palermo, Vincenzo De Luca & Andrea de Bartolomeis. (2019) Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis. Frontiers in Psychiatry 10.
Crossref
Crossref
Signe W. Düring, Mette Ø. Nielsen, Nikolaj Bak, Birte Y. Glenthøj & Bjørn H. Ebdrup. (2019) Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade – An exploratory study. Psychiatry Research 274, pages 58-65.
Crossref
Crossref
Mary V. Seeman. (2018) Does Gender Influence Outcome in Schizophrenia?. Psychiatric Quarterly 90:1, pages 173-184.
Crossref
Crossref
Paola Bozzatello, Silvio Bellino & Paola Rocca. (2019) Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Frontiers in Psychiatry 10.
Crossref
Crossref
Daniel Schöttle & Jürgen Gallinat. (2019) Neugestaltung einer Akutpsychiatrie – ein WerkstattberichtReorganization of acute psychiatry—a workshop report. Forensische Psychiatrie, Psychologie, Kriminologie 13:1, pages 13-21.
Crossref
Crossref
Demet Sağlam Aykut. (2019) Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life. Journal of Clinical Psychopharmacology 39:1, pages 57-62.
Crossref
Crossref
S. Barlati, G. Deste, M. Gregorelli & A. Vita. (2018) Autistic traits in a sample of adult patients with schizophrenia: prevalence and correlates. Psychological Medicine 49:1, pages 140-148.
Crossref
Crossref
Sameer Jauhar, Mattia Veronese, Matthew M. Nour, Maria Rogdaki, Pamela Hathway, Sridhar Natesan, Federico Turkheimer, James Stone, Alice Egerton, Philip McGuire, Shitij Kapur & Oliver D. Howes. (2019) The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry 85:1, pages 79-87.
Crossref
Crossref
Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U. Correll & Klaus Wiedemann. (2018) Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry 18:1.
Crossref
Crossref
Peter M. Haddad & Christoph U. Correll. (2018) The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic Advances in Psychopharmacology 8:11, pages 303-318.
Crossref
Crossref
Atipatsa Chiwanda KamingaWenjie Dai, Aizhong Liu, Japhet Myaba, Richard Banda, Shi Wu WenXiongfeng Pan. (2018) Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi. Medicine 97:45, pages e13078.
Crossref
Crossref
Andrew T. Olagunju, Scott R. Clark & Bernhard T. Baune. (2018) Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. CNS Drugs 32:11, pages 1011-1023.
Crossref
Crossref
Tomoyuki Nagata, Shunichiro Shinagawa, Shinichiro Nakajima, Masaru Mimura & Masahiro Shigeta. (2018) Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer’s Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease 66:1, pages 139-148.
Crossref
Crossref
Mingli Li, Wei Deng, Tushar Das, Yinfei Li, Liansheng Zhao, Xiaohong Ma, Yingcheng Wang, Hua Yu, Xiaojing Li, Ya-jing Meng, Qiang Wang, Lena Palaniyappan & Tao Li. (2017) Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study. European Archives of Psychiatry and Clinical Neuroscience 268:7, pages 641-651.
Crossref
Crossref
Eva Velthorst, Sean Froudist-Walsh, Eli Stahl, Douglas Ruderfer, Ilyan Ivanov, Joseph Buxbaum, Anders D. Børglum, Jakob Grove, Manuel Mattheisen, Thomas Werge, Preben Bo Mortensen, Marianne Giørtz Pedersen, Carsten Bøcker Pedersen, Ole Mors, Merete Nordentoft, David M. Hougaard, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, Christine Søholm Hansen, Mark J. Daly, Benjamin M. Neale, Elise B Robinson, Felecia Cerrato, Ashley Dumont, Jacqueline Goldstein, Christine Stevens, Raymond Walters, Claire Churchhouse, Stephan Ripke, Joanna Martin, Tobias Banaschewski, Arun L. W. Bokde, Uli Bromberg Dipl-Psych, Christian Büchel, Erin Burke Quinlan, Sylvane Desrivières, Herta Flor, Vincent Frouin, Hugh Garavan, Penny Gowland, Andreas Heinz, Bernd Ittermann, Marie-Laure Paillère Martinot, Eric Artiges, Frauke Nees, Dimitri Papadopoulos Orfanos, Tomáš Paus, Luise Poustka, Sarah Hohmann, Juliane H. Fröhner, Michael N. Smolka, Henrik Walter, Robert Whelan, Gunter Schumann & Abraham Reichenberg. (2018) Genetic risk for schizophrenia and autism, social impairment and developmental pathways to psychosis. Translational Psychiatry 8:1.
Crossref
Crossref
Yazed AlRuthia, Hadeel Alkofide, Fahad Dakheel Alosaimi, Hisham Alkadi, Albandari Alnasser, Aliah Aldahash, Arwa Basalamah & Maryam Alarfaj. (2018) Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in Arabic. PLOS ONE 13:8, pages e0201225.
Crossref
Crossref
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang & Yu Feng. (2018) Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Journal of Psychopharmacology 32:6, pages 691-701.
Crossref
Crossref
Christoph U. Correll, Jose M. Rubio & John M. Kane. (2018) What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?. World Psychiatry 17:2, pages 149-160.
Crossref
Crossref
Ross M.G. Norman, Arlene MacDougall, Rahul Manchanda & Raj Harricharan. (2018) An examination of components of recovery after five years of treatment in an early intervention program for psychosis. Schizophrenia Research 195, pages 469-474.
Crossref
Crossref
Claire Ramsay Wan & Beth Broussard. 2018. The Complex Connection Between Cannabis and Schizophrenia. The Complex Connection Between Cannabis and Schizophrenia
247
269
.
Jeffrey P. Anderson, Zeynep Icten, Veronica Alas, Carmela Benson & Kruti Joshi. (2017) Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 17:1.
Crossref
Crossref
Amy L. Gillespie, Ruta Samanaite, Jonathan Mill, Alice Egerton & James H. MacCabe. (2017) Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry 17:1.
Crossref
Crossref
Tomoyuki Nagata, Shinichiro Nakajima, Shunichiro Shinagawa, Eric Plitman, Kazuhiko Nakayama, Ariel Graff-Guerrero & Masaru Mimura. (2017) Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer’s Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease 60:1, pages 263-272.
Crossref
Crossref
Noa A Brzezinski-Sinai & Mary V Seeman. (2017) Women and schizophrenia: planning for the future. Future Neurology 12:2, pages 89-99.
Crossref
Crossref
Robin Murray, Christoph U. Correll, Gavin P. Reynolds & David Taylor. (2017) Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Therapeutic Advances in Psychopharmacology 7:1_suppl, pages 1-14.
Crossref
Crossref
W. Zheng, Y.‐T. Xiang, Y.‐Q. Xiang, X.‐B. Li, G. S. Ungvari, H. F. K. Chiu & C. U. Correll. (2016) Efficacy and safety of adjunctive topiramate for schizophrenia: a meta‐analysis of randomized controlled trials. Acta Psychiatrica Scandinavica 134:5, pages 385-398.
Crossref
Crossref
Ashok Malla, Ai Ota, Kazuhiro Nagamizu, Pamela Perry, Emmanuelle Weiller & Ross A. Baker. (2016) The effect of brexpiprazole in adult outpatients with early-episode schizophrenia. International Clinical Psychopharmacology 31:6, pages 307-314.
Crossref
Crossref
J. Lally, O. Ajnakina, M. Di Forti, A. Trotta, A. Demjaha, A. Kolliakou, V. Mondelli, T. Reis Marques, C. Pariante, P. Dazzan, S. S. Shergil, O. D. Howes, A. S. David, J. H. MacCabe, F. Gaughran & R. M. Murray. (2016) Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine 46:15, pages 3231-3240.
Crossref
Crossref
Vijay Kumar, Naren P. Rao, Venkatalakshmi Narasimha, Gopinath Sathyanarayanan, Kesavan Muralidharan, Shivarama Varambally, Ganesan Venkatasubramanian & Bangalore N. Gangadhar. (2016) Antipsychotic dose in maintenance treatment of schizophrenia: A retrospective study. Psychiatry Research 245, pages 311-316.
Crossref
Crossref
E.J. Brandl, T.A. Lett, N.I. Chowdhury, A.K. Tiwari, G. Bakanidze, H.Y. Meltzer, S.G. Potkin, J.A. Lieberman, J.L. Kennedy & D.J. Müller. (2016) The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophrenia Research 176:2-3, pages 131-135.
Crossref
Crossref
Alp Üçok, Ugur Çıkrıkçılı, Ceylan Ergül, Öznur Tabak, Ada Salaj, Sercan Karabulut & Christoph U. Correll. (2016) Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS Drugs 30:10, pages 997-1006.
Crossref
Crossref
Christoph U. Correll, Aleksandar Skuban, Mary Hobart, John Ouyang, Emmanuelle Weiller, Catherine Weiss & John M. Kane. (2016) Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophrenia Research 174:1-3, pages 82-92.
Crossref
Crossref
Marie Stentebjerg-OlesenAnne K. PagsbergAnders Fink-JensenChristoph U. CorrellPia Jeppesen. (2016) Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. Journal of Child and Adolescent Psychopharmacology 26:5, pages 410-427.
Crossref
Crossref
Steffen Moritz & Brooke C. Schneider. (2016) From the Incomprehensible to the Partially Understood. An Update on Cognitive Bias Research and Metacognitive Training in Schizophrenia Psychosis. Current Treatment Options in Psychiatry 3:2, pages 83-98.
Crossref
Crossref
Theresa Wimberley, Henrik Støvring, Holger J Sørensen, Henriette T Horsdal, James H MacCabe & Christiane Gasse. (2016) Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. The Lancet Psychiatry 3:4, pages 358-366.
Crossref
Crossref
Tomasz Pawełczyk, Marta Grancow-Grabka, Magdalena Kotlicka-Antczak, Elżbieta Trafalska & Agnieszka Pawełczyk. (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Journal of Psychiatric Research 73, pages 34-44.
Crossref
Crossref
Marie Stentebjerg-Olesen, Stephen J. Ganocy, Robert L. Findling, Kiki Chang, Melissa P. DelBello, John M. Kane, Mauricio Tohen, Pia Jeppesen & Christoph U. Correll. (2015) Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. European Child & Adolescent Psychiatry 24:12, pages 1485-1496.
Crossref
Crossref
René S. Kahn, Iris E. Sommer, Robin M. Murray, Andreas Meyer-Lindenberg, Daniel R. Weinberger, Tyrone D. Cannon, Michael O'Donovan, Christoph U. Correll, John M. Kane, Jim van Os & Thomas R. Insel. (2015) Schizophrenia. Nature Reviews Disease Primers 1:1.
Crossref
Crossref
Qian Li, Yu-Tao Xiang, Yun-Ai Su, Liang Shu, Xin Yu, Christoph U. Correll, Gabor S. Ungvari, Helen F.K. Chiu, Cui Ma, Gao-Hua Wang, Pei-Shen Bai, Tao Li, Li-Zhong Sun, Jian-Guo Shi, Xian-Sheng Chen, Qi-Yi Mei, Ke-Qing Li, Tian-Mei Si & John M. Kane. (2015) Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012). Schizophrenia Research 168:1-2, pages 523-529.
Crossref
Crossref